Gilead to buy Nimbus Therapeutics' NASH programme for up to $1.2 billion

Gilead Sciences announced Monday a definitive agreement to acquire Nimbus Therapeutics' Nimbus Apollo unit and its acetyl-CoA carboxylase (ACC) inhibitor programme, which is focused on the treatment of non-alcoholic steatohepatitis (NASH), for up to $1.2 billion. The deal includes an upfront payment of $400 million, with the potential development-related milestones of up to $800 million.

Norbert Bischofberger, Gilead's chief scientific officer, remarked that the transaction "represents a timely and important opportunity to accelerate Gilead's ongoing efforts to address unmet needs in NASH." The executive continued "these molecules will complement and further strengthen Gilead's pipeline and capabilities to advance a broad clinical programme in NASH that includes compounds targeting multiple key pathways involved in the pathogenesis of the disease."

The Nimbus Apollo programme includes the lead candidate and ACC inhibitor NDI-010976, in addition to other preclinical ACC inhibitors for the treatment of NASH and potentially other diseases including hepatocellular carcinoma. NDI-010976 was granted fast track designation by the FDA in February for the treatment of NASH. Phase I study data for the therapy is scheduled to be presented at the annual meeting of the European Association for the Study of the Liver (EASL) in May.

Following closing of the transaction, Nimbus Apollo will be a fully owned subsidiary of Gilead, which will hold exclusive responsibility for the development and commercialisation of NDI-010976 and the other ACC inhibitors in the programme.

For more information on drugs under development for the treatment of NASH, see Nonalcoholic Steatohepatitis: KOL Insight.

To read more Top Story articles, click here.